Braun-Falco O, Schmoeckel C, Hubner G, 1976. The histogenesis of Kaposi sarcoma: a histochemical and electronmicroscopical study (in German). Virchows Arch A Pathol Anat Histol 369: 215–227.
Alessandri G, Fiorentini S, Licenziati S, Bonafede M, Monini P, Ensoli B, Caruso A, 2003. CD8(+)CD28(−) T lymphocytes from HIV-1-infected patients secrete factors that induce endothelial cell proliferation and acquisition of Kaposi's sarcoma cell features. J Interferon Cytokine Res 23: 523–531.
Brown LF, Dezube BJ, Tognazzi K, Dvorak HF, Yancopoulos GD, 2000. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 156: 2179–2183.
Graham SM, Rajwans N, Jaoko W, Estambale BB, McClelland RS, Overbaugh J, Liles WC, 2013. Endothelial activation biomarkers increase after HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts disease progression. AIDS 27: 1803–1813.
Graham SM, Rajwans N, Tapia KA, Jaoko W, Estambale BB, McClelland RS, Overbaugh J, Liles WC, 2013. A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy. BMC Infect Dis 13: 263.
Taylor JF, Smith PG, Bull D, Pike MC, 1972. Kaposi's sarcoma in Uganda: geographic and ethnic distribution. Br J Cancer 26: 483–497.
Asiimwe F, Moore D, Were W, Nakityo R, Campbell J, Barasa A, Mermin J, Kaharuza F, 2012. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda. HIV Med 13: 166–171.
GLOBOCAN, 2012. Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed March 24, 2014.
Maskew M, Fox MP, van Cutsem G, Chu K, Macphail P, Boulle A, Egger M, Africa FI, 2013. Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study. PLoS ONE 8: e64392.
Martin HL Jr, Jackson DJ, Mandaliya K, Bwayo J, Rakwar JP, Nyange P, Moses S, Ndinya-Achola JO, Holmes K, Plummer F, 1994. Preparation for AIDS vaccine evaluation in Mombasa, Kenya: establishment of seronegative cohorts of commercial sex workers and trucking company employees. AIDS Res Hum Retroviruses 10 (Suppl 2): S235–S237.
World Health Organization, 2010. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 2010 Update. Geneva: World Health Organization.
Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, Panteleeff D, Jagodzinski LL, Michael NL, Nduati R, Bwayo J, Kreiss JK, Overbaugh J, 2000. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol 38: 2688–2695.
Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Mäkinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C, 2004. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36: 687–693.
Pati S, Cavrois M, Guo HG, Foulke JS Jr, Kim J, Feldman RA, Reitz M, 2001. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J Virol 75: 8660–8673.
Kelly GD, Ensoli B, Gunthel CJ, Offermann MK, 1998. Purified Tat induces inflammatory response genes in Kaposi's sarcoma cells. AIDS 12: 1753–1761.
Offermann MK, Lin JC, Mar EC, Shaw R, Yang J, Medford RM, 1996. Antioxidant-sensitive regulation of inflammatory-response genes in Kaposi's sarcoma cells. J Acquir Immune Defic Syndr Hum Retrovirol 13: 1–11.
Galea P, Frances V, Dou-Dameche L, Sampol J, Chermann JC, 1998. Role of Kaposi's sarcoma cells in recruitment of circulating leukocytes: implications in pathogenesis. J Hum Virol 1: 273–281.
Huang YQ, Friedman-Kien AE, Li JJ, Nickoloff BJ, 1993. Cultured Kaposi's sarcoma cell lines express factor XIIIa, CD14, and VCAM-1, but not factor VIII or ELAM-1. Arch Dermatol 129: 1291–1296.
Uccini S, Ruco LP, Monardo F, Stoppacciaro A, Dejana E, La Parola IL, Cerimele D, Baroni CD, 1994. Co-expression of endothelial cell and macrophage antigens in Kaposi's sarcoma cells. J Pathol 173: 23–31.
Sciacca FL, Sturzl M, Bussolino F, Sironi M, Brandstetter H, Zietz C, Zhou D, Matteucci C, Peri G, Sozzani S, 1994. Expression of adhesion molecules, platelet-activating factor, and chemokines by Kaposi's sarcoma cells. J Immunol 153: 4816–4825.
Becker K, Heins M, Sudhoff T, Reinauer H, Haussinger D, 1997. Specific pattern of circulating endothelial adhesion molecules in HIV-associated Kaposi's sarcoma. Int Arch Allergy Immunol 113: 512–515.
De Paoli P, Caffau C, D'Andrea M, Tavio M, Tirelli U, Santini G, 1994. Serum levels of intercellular adhesion molecule 1 in patients with HIV-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 7: 695–659.
Vart RJ, Nikitenko LL, Lagos D, Trotter MW, Cannon M, Bourboulia D, Gratrix F, Takeuchi Y, Boshoff C, 2007. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res 67: 4042–4051.
Ye FC, Zhou FC, Nithianantham S, Chandran B, Yu XL, Weinberg A, Gao SJ, 2013. Kaposi's sarcoma-associated herpesvirus induces rapid release of angiopoietin-2 from endothelial cells. J Virol 87: 6326–6335.
Dezube BJ, Sullivan R, Koon HB, 2006. Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: bidirectional translational science. J Cell Physiol 209: 659–662.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 29 | 29 | 8 |
Full Text Views | 285 | 88 | 0 |
PDF Downloads | 48 | 15 | 0 |
Circulating levels of endothelial activation biomarkers are elevated in during infection with human immunodeficiency virus 1 (HIV-1) and may also be increased in Kaposi sarcoma (KS). We compared 23 HIV-1-seropositive women with clinically diagnosed KS with 46 randomly selected controls matched for visit year, CD4 count, and antiretroviral therapy status. Conditional logistic regression was used to identify differences between cases and controls. The odds of clinical KS increased with increasing plasma viral load and with intercellular adhesion molecule 1 (ICAM-1) levels above or equal to the median. There was a borderline association between increasing plasma angiopoietin 2 levels and KS. In multivariable modeling including plasma viral load, angiopoietin 2, and ICAM-1, plasma ICAM-1 levels above or equal to the median remained associated with clinical KS (odds ratio = 14.2, 95% confidence interval = 2.3–87.7). Circulating ICAM-1 levels should be evaluated as a potential biomarker for disease progression and treatment response among HIV-infected KS patients.
Financial support: This study was supported by a New Investigator Award to Susan M. Graham from the University of Washington Center for AIDS Research, which is supported the National Institutes of Health (NIH) (grant no. P30 AI027757); the National Institute of Allergy and Infectious Diseases, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Institute of Child Health and Human Development, the National Heart, Lung, and Blood Institute, and the National Institute on Aging (grants AI-58698 and AI-38518); and by a Canada Research Chair in Infectious Diseases and Inflammation to W. Conrad Liles from the Canadian Institutes for Health Research.
Disclosure: W. Conrad Liles is listed as a co-inventor on a patent applied for by the University Health Network (Toronto, ON, Canada) to develop point-of-care tests for endothelial activation biomarkers in infectious diseases. All other authors report no conflicts of interest.
Authors' addresses: Susan M. Graham, Barbra A. Richardson, R. Scott McClelland, and W. Conrad Liles, University of Washington, Seattle, WA, E-mails: grahamsm@uw.edu, barbrar@uw.edu, mcclell@uw.edu, and wcliles@uw.edu. Nimerta Rajwans, University Health Network, Toronto Medical Discovery Tower, Toronto, Ontario, Canada, E-mail: nimerta1@hotmail.com. Walter Jaoko, University of Nairobi, Nairobi, Kenya, E-mail: wjaoko07@gmail.com. Julie Overbaugh, Fred Hutchinson Cancer Research Center, Seattle, WA, E-mail: joverbau@fhcrc.org.
Braun-Falco O, Schmoeckel C, Hubner G, 1976. The histogenesis of Kaposi sarcoma: a histochemical and electronmicroscopical study (in German). Virchows Arch A Pathol Anat Histol 369: 215–227.
Alessandri G, Fiorentini S, Licenziati S, Bonafede M, Monini P, Ensoli B, Caruso A, 2003. CD8(+)CD28(−) T lymphocytes from HIV-1-infected patients secrete factors that induce endothelial cell proliferation and acquisition of Kaposi's sarcoma cell features. J Interferon Cytokine Res 23: 523–531.
Brown LF, Dezube BJ, Tognazzi K, Dvorak HF, Yancopoulos GD, 2000. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 156: 2179–2183.
Graham SM, Rajwans N, Jaoko W, Estambale BB, McClelland RS, Overbaugh J, Liles WC, 2013. Endothelial activation biomarkers increase after HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts disease progression. AIDS 27: 1803–1813.
Graham SM, Rajwans N, Tapia KA, Jaoko W, Estambale BB, McClelland RS, Overbaugh J, Liles WC, 2013. A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy. BMC Infect Dis 13: 263.
Taylor JF, Smith PG, Bull D, Pike MC, 1972. Kaposi's sarcoma in Uganda: geographic and ethnic distribution. Br J Cancer 26: 483–497.
Asiimwe F, Moore D, Were W, Nakityo R, Campbell J, Barasa A, Mermin J, Kaharuza F, 2012. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda. HIV Med 13: 166–171.
GLOBOCAN, 2012. Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed March 24, 2014.
Maskew M, Fox MP, van Cutsem G, Chu K, Macphail P, Boulle A, Egger M, Africa FI, 2013. Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study. PLoS ONE 8: e64392.
Martin HL Jr, Jackson DJ, Mandaliya K, Bwayo J, Rakwar JP, Nyange P, Moses S, Ndinya-Achola JO, Holmes K, Plummer F, 1994. Preparation for AIDS vaccine evaluation in Mombasa, Kenya: establishment of seronegative cohorts of commercial sex workers and trucking company employees. AIDS Res Hum Retroviruses 10 (Suppl 2): S235–S237.
World Health Organization, 2010. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 2010 Update. Geneva: World Health Organization.
Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, Panteleeff D, Jagodzinski LL, Michael NL, Nduati R, Bwayo J, Kreiss JK, Overbaugh J, 2000. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol 38: 2688–2695.
Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Mäkinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C, 2004. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36: 687–693.
Pati S, Cavrois M, Guo HG, Foulke JS Jr, Kim J, Feldman RA, Reitz M, 2001. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J Virol 75: 8660–8673.
Kelly GD, Ensoli B, Gunthel CJ, Offermann MK, 1998. Purified Tat induces inflammatory response genes in Kaposi's sarcoma cells. AIDS 12: 1753–1761.
Offermann MK, Lin JC, Mar EC, Shaw R, Yang J, Medford RM, 1996. Antioxidant-sensitive regulation of inflammatory-response genes in Kaposi's sarcoma cells. J Acquir Immune Defic Syndr Hum Retrovirol 13: 1–11.
Galea P, Frances V, Dou-Dameche L, Sampol J, Chermann JC, 1998. Role of Kaposi's sarcoma cells in recruitment of circulating leukocytes: implications in pathogenesis. J Hum Virol 1: 273–281.
Huang YQ, Friedman-Kien AE, Li JJ, Nickoloff BJ, 1993. Cultured Kaposi's sarcoma cell lines express factor XIIIa, CD14, and VCAM-1, but not factor VIII or ELAM-1. Arch Dermatol 129: 1291–1296.
Uccini S, Ruco LP, Monardo F, Stoppacciaro A, Dejana E, La Parola IL, Cerimele D, Baroni CD, 1994. Co-expression of endothelial cell and macrophage antigens in Kaposi's sarcoma cells. J Pathol 173: 23–31.
Sciacca FL, Sturzl M, Bussolino F, Sironi M, Brandstetter H, Zietz C, Zhou D, Matteucci C, Peri G, Sozzani S, 1994. Expression of adhesion molecules, platelet-activating factor, and chemokines by Kaposi's sarcoma cells. J Immunol 153: 4816–4825.
Becker K, Heins M, Sudhoff T, Reinauer H, Haussinger D, 1997. Specific pattern of circulating endothelial adhesion molecules in HIV-associated Kaposi's sarcoma. Int Arch Allergy Immunol 113: 512–515.
De Paoli P, Caffau C, D'Andrea M, Tavio M, Tirelli U, Santini G, 1994. Serum levels of intercellular adhesion molecule 1 in patients with HIV-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 7: 695–659.
Vart RJ, Nikitenko LL, Lagos D, Trotter MW, Cannon M, Bourboulia D, Gratrix F, Takeuchi Y, Boshoff C, 2007. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res 67: 4042–4051.
Ye FC, Zhou FC, Nithianantham S, Chandran B, Yu XL, Weinberg A, Gao SJ, 2013. Kaposi's sarcoma-associated herpesvirus induces rapid release of angiopoietin-2 from endothelial cells. J Virol 87: 6326–6335.
Dezube BJ, Sullivan R, Koon HB, 2006. Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: bidirectional translational science. J Cell Physiol 209: 659–662.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 29 | 29 | 8 |
Full Text Views | 285 | 88 | 0 |
PDF Downloads | 48 | 15 | 0 |